Latest Breaking News On - Joshua higa - Page 1 : vimarsana.com

Ultragenyx Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants

NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) Ultragenyx

United statesNew yorkJoshua higaUltragenyx pharmaceuticalincTd securities united statesJp morgan securitiesGoldman sachs coExchange commissionBroadridge financial solutionsProspectus departmentContact ultragenyx pharmaceutical incExchange commission onGoldman sachsBofa securitiesIsland avenueTryon street

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomChristine foxGarys gottesmanCarolyn wangJoshua higaMereo biopharmaDenise scots knightLee rothUnited states securities exchangeMereo biopharma groupUltragenyx pharmaceutical incExchange commissionWashington university school of medicineWashington university school

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomDenise scots knightCarolyn wangMereo biopharmaJoshua higaLee rothChristine foxGarys gottesmanUnited states securities exchangeMereo biopharma groupUltragenyx pharmaceutical incExchange commissionWashington university school of medicineWashington university school

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare

Joshua higaCarolyn wangEmil kakkisGoldman sachsUltragenyx pharmaceutical incAnnual global healthcare conferenceUltragenyx pharmaceutical

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJoshua higaCarolyn wangUltragenyx pharmaceutical incExchange commissionEuropean medicines agencyDisease monitoring programData presented at american society of geneAmerican societyCell therapyConference callFast trackEuropean medicinesForward looking statementsPrivate securities litigation reform actQuarterly report